Leveraging Innovation for Faster Treatment of Tuberculosis

Introducing Highly Effective New Treatment Regimens for Tuberculosis
LIFT TB aims to accelerate implementation of short regimens for DR-TB

Save lives and livelihoods of TB patients, their families and communities in **seven target countries through**:

- Increase **treatment completion rates** for DR-TB through adoption of BPaL
- Broaden **availability and sustainability** of BPaL

**Target Country**
- Myanmar
- Philippines
- Indonesia
- Vietnam
- EECA
- Kyrgyzstan
- Uzbekistan
- Ukraine

**Project Sponsor**
- KOICA
- MoFA
- GDEF
- S. Korea
- TB Alliance
  - NY, USA
Treatment success rates for MDR/XDR-TB remain low, and yet uptake of novel drugs has historically taken very long.

Focused efforts are needed to catalyze accelerated transition to new effective regimens.

**Treatment success rates (2017 cohort)**

- MDR-TB: 0%
- XDR-TB: 20%

**Years to market availability for new TB drugs after SRA approval**

- NCE 1:
  - 1st non SRA approval: 1 year
  - 1st procurement (GDF): 2 years

- NCE 2:
  - 1st non SRA approval: 4 years
  - 1st procurement (GDF): 5 years

Source: Global Tuberculosis Report, WHO, 2020

Source: GDF, Pharma Standard, Otsuka
LIFT TB will provide catalytic support to overcome key access barriers

Increase treatment completion rates

A. Evidence generation
   • Operational research
   • Harmonized data collection and ongoing reporting
     • To inform WHO guidelines
     • National guideline update

B. Capacity building for the use of new regimens
   • Development of training materials
   • Clinical and lab trainings
   • Development of job aids and SOPs

C. National scale-up of new regimens
   • Dissemination of additional evidence and best practices
   • National scale-up planning
   • DST strengthening

Broaden availability and sustainability

A. Ensuring in-country availability
   • Regulatory filings
   • Support catalytic procurement of drugs and diagnostic commodities

B. Ensuring sustainability
   • Support integration into national budgets, grants and reprogramming
   • Disseminate project experience regionally and globally
Partnership will be key for success

- Project coordination and delivery in the Philippines and Myanmar
- Laboratory trainings & strengthening
- Support aDSM in the Philippines and Myanmar
- Knowledge sharing and dissemination

Commercial Partners

- Project oversight
- Global stakeholder engagement
- Evidence dissemination
- Scientific support & training (with Mylan)
- Support catalytic procurement

National TB Programs

- Operational research
- Clinical trainings
- Support for national guidelines update
- Support for national scale-up planning
- Resource mobilization

Global Stakeholders

- WHO
- Global Fund
- Global Drug Facility
- Others
Acknowledgements & the team

- Aastha Gupta
- Agnes Gebhard
- Ana Maria Harkins
- Andrii Slyzkyi
- Angela Vanderploeg
- Bakyt Mirzayev
- Christi Baine
- Farha Butt Khaja
- Fraser Wares
- Huong Nguyen
- Hyejon Lee
- Inge Koppelar
- Ino Choi
- Jessica Wiggs
- Jhon Sugiharto
- Jinhee Lee
- Jongseok Lee
- Katja Lumelova
- Mamal Quelapio
- Mansa Mbenga
- Mavluda Makhmudova
- Melvin Spigelman
- Myungsun Lee
- Naoko Doi
- Nathalie Veenman
- Ray Cho
- Robert Lorette
- Sandeep Juneja
- Sarah Cook Scalise
- Sharaf Yuldashev
- Svetlana Pak
- Trudy Kline
- Thomas Lynch
- Unyeong Go
- Veriko Mirtskhulava
- Willo Brock
- Zvia Shwirtz
This work is made possible by generous support from…
LIFTB
Leveraging Innovation for Faster Treatment of Tuberculosis